In vitro cell culture systems as the basis for an extracorporeal blood purification strategy in multiorgan failure treatment

Therapeutic Apheresis

Volumn 3, Issue 3, 1999, Pages 257-263

  Mitteregger, Regina ^a   White, Adrienne ^a   Weber, Christoph ^a   Rossmanith, Eva ^a   Mohr, Thomas ^b   Micksche, Michael ^b   Falkenhagen, Dieter ^a  

^a DANUBE UNIVERSITY KREMS   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adsorber; Blood purification; Cytokine; Endotoxin; Multiorgan failure

Indexed keywords

CYTOKINE; ENDOTOXIN; INTERCELLULAR ADHESION MOLECULE 1; MICROSPHERE; POLYCLONAL ANTIBODY; POLYSTYRENE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CELL CULTURE; CELL INTERACTION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACORPOREAL CIRCULATION; HUMAN; HUMAN CELL; IMMUNOADSORBENT; MONONUCLEAR CELL; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PURIFICATION;

CELLS, CULTURED; DEAE-CELLULOSE; ENDOTHELIUM, VASCULAR; ENDOTOXINS; HEMOPERFUSION; HUMANS; IMMUNOSORBENT TECHNIQUES; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES, MONONUCLEAR; MICROSPHERES; MULTIPLE ORGAN FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032810247     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.1999.00167.x     Document Type: Article

References (36)

1. Krul KG. Sepsis therapeutics: A history of unfulfilled promises. Biotechnol Appl 1993;40:1-15.
2. Tran DD, Groeneveld ABJ, Van der Meulen J, Nauta JJP, Strack van Schijndel RJM, Thijs LG. Age, chronic disease, sepsis, organ system failure and mortality in a medical intensive care unit. Crit Care Med 1990;18:474-9.
3. Hebert PC, Drummond AJ, Singer J, Bernard GR, Russel JA. A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest 1993;104:230-5.
4. Kluge M, Kaul M. Tumor necrosis factor-neutralization with a specific monoclonal antibody. Reprint from: Sepsis. Eyrich K, Reinhart K, Sprung CL, eds. Berlin, Heidelberg: Springer-Verlag, 1994:349-56.
5. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: Pathogenesis. Lancet 1991;338:732.
6. Stegmayr BG. Plasmapheresis in severe sepsis or septic shock. Blood Purif 1996;14:94-101.
7. Jaber BL, Pereira BJG. Inflammatory mediators in sepsis: A rationale for extracorporeal therapies? Am J Kidney Dis 1996; 28:35-49.
8. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1829.
9. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, Seed B. Endothelial leukocyte adhesion molecule 1: An inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989;243:1160-5.
10. Pober JS, Bevilacqua MP, Mendrick D, Lapierre LA, Fiers W, Gimbrone MA Jr. Two distinct monokines, interleukin-1 and tumor necrosis factor, each independently induces biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cell. J Immunol 1986; 136:1680-7.
11. De Vriese AS, Vanholder RC, De Sutter JH, Colardyn FA, Lameire NH. Continuous renal replacement therapies in sepsis: Where are the data? Nephrol Dial Transplant 1998;13: 1362-4.
12. Bauer M. Pathophysiologie der Sepsis-Aktuelle Konzepte. Anästhesist 1996;45:313-322.
13. Weber C, Rajnoch C, Loth U, Schima H, Falkenhagen D. The microspheres based detoxification system (MDS). A new extracorporeal blood purification technology based on recirculated microspherical adsorbent particles. Int J Artif Organs 1994,17:595-602.
14. Van Appen K, Weber C, Losert U, Schima H, Gurland HJ, Falkenhagen D. Microspheres base detoxification system: A new method in convective blood purification. Artif Organs 1996;20(5):420-5.
15. Weber C, Falkenhagen D. Specific blood purification by means of antibody-conjugated magnetic microspheres. In: Häfeli U, Schütt W, Teller J, Zborowski M, eds. Scientific and clinical applications of magnetic carriers. New York: Plenum Press, 1997:371-8.
16. Strobl W, Falkenhagen D. Möglichkeiten einer extrakorporealen Elimination von Zytokinen bzw. zytokininduzierenden Substanzen beim Multiorganversagen. Dialyse J 1998;17(61): 82-91.
17. Kaplan AA, Bailey RA, Kew CE, Reardon J, Sevign J. High flux plasma exchange using a modified rotating membrane system. ASAIO J 1996;42:957-60.
18. Nocker WA, Scherberich JE. Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: Evidence for chronic exposure to LPS. Kidney Int 1995;48: 1469-76.
19. Schütt C, Schilling T, Grunwald U, Schönfeld W, Krüger C. Endotoxin-neutralizing capacity of soluble CD14. Res Immunol 1992;143:71-8.
20. Frey EA, Miller DS, Gullstein Jahr T, Sundan A, Bazil V, Espevik T, Finaly BB, Wright SD. Soluble CD14 participates in the response of cells to lipopolysaccharides. J Exp Med 1992;176:1665-71.
21. Haziot A, Rong GW, Silver J, Goyert SM. Recombinant soluble CD14 mediates the activation of endothelial cells by lipopolysaccharide. J Immunol 1993;151:1500-7.
22. Tracey KJ, Vlassara H, Cerami A. Cachectin tumor necrosis factor. Lancet 1989;2:1122.
23. Cohen J, Glauser MP. Septic shock treatment. Lancet 1991; 338:736.
24. Osborn L, Hession C, Tizard R, Vassalli C, Luhowskyj S, Chi-Rosso G, Lobb R. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989;59:1203-11.
25. Montefort S, Holgate ST, Howarth PH. Leukocyte adhesion molecules and their role in bronchial asthma and allergic rhinitis. Eur Respir J 1993;6:1044-54.
26. Calderon E, Lockey RF. A possible role for adhesion molecules in asthma. J Allergy Clin Immunol 1992;90:852-65.
27. Guzman J, Izumi T, Nagai S, Costabel U. ICAM-1 and integrin expression on isolated human alveolar tye II pneumocytes. Eur Respir J 1994;7:736-9.
28. Du bois RM, Hellewell PG, Hemingway I, Gearing AJ. Soluble cell adhesion molecules ICAM-1, ELAM-1 and VCAM-1 are present in epithelial lining fluid in patients with interstitial lund disease. Am Rev Respir Dis 1992;145:190.
29. Seth R, Raymond FD, Makgoba MW. Circulating ICAM-1 isoforms: Diagnostic prospects for inflammatory and immune disorders. Lancet 1991;338:83-4.
30. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-8.
31. Falkenhagen D. Small particles in medicine. Artif Organs 1995;19:792-4.
32. Gimbrone MA. Progress in hemostasis and thrombosis. In: Spaet, TH, ed. New York: Grune & Stratton, 1976;3:1-28.
33. Aoki H, Kodama M, Tani T, Hanashava K. Treatment of sepsis by extracorporeal elimination of endotoxins using polymyxin-B-immobilized fiber. Am J Surg 1994;167(4):412-7.
34. Kodama M, Tani T, Maekava K, Hirasava H, Otsuka T, Takahashi Y, Kaneko M. Endotoxin eliminating therapy in patients with severe sepsis - direct hemoperfusion using polymyxinB immobilized fiber column. Nippon Geka Gakkai Zasshi 1995;96(5):277-85.
35. Weber C, Henne B, Loth F, Schoenhofen M, Falkenhagen D. Development of cationically modified cellulose adsorbents for the removal of endotoxins. ASAIO J 1995;41:430-4.
36. Saravolatz LD, Pokriefka RA, Markowitz N. Monoclonal antibodies against TNF: A non-antibiotic strategy for the treatment of sepsis. In: Vincent JL, ed. Yearbook of intensive care and emergency medicine. Berlin, Heidelberg, New York: Springer, 1993:100.